Harlan Saul Robins

USPTO Granted Patents = 31 (Patent Applications = 24)

CIPO Patents = 4 (Patent Applications = 7)

EPO Patents = 18 (Patent Applications = 26)

Average Co-Inventor Count = 3.0

ph-index = 9

Forward Citations = 231(Granted Patents)

Company Filing History:

25 out of 56

Adaptive Biotechnologies Corporation

patents

11 out of 289

Fred Hutchinson Cancer Center

patents

3 out of 559

Memorial Sloan Kettering Cancer Center

patents

4. 1 out of 2

Institute of Advanced Study

patents

5. 1 out of 1

Digital Biotechnologies, Inc.

patent

6. 1 out of 1

Institute for Advanced Study

patent

where one patent can have more than one assignee

Years Active: 2015-2025

Loading Chart...

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12428682 - Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing (2025-09-30),

2. 12351869 - Nucleic acid sequencing compositions and methods (2025-07-08),

3. 12266425 - T cell receptor sequences diagnostic for COVID-19 and related compositions (2025-04-01),

4. 12263179 - Lyme disease-associated T cell receptor-related methods (2025-04-01),

5. 12195795 - Synthetic strands for nucleic acid sequencing and related methods and systems (2025-01-14),

6. 12104211 - Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization (2024-10-01),

7. 11905511 - Method of measuring adaptive immunity (2024-02-20),

8. 11708605 - Synthetic strands for nucleic acid sequencing and related methods and systems (2023-07-25),

9. 11254980 - Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements (2022-02-22),

10. 11248253 - Methods using randomer-containing synthetic molecules (2022-02-15),

11. 11214793 - Method of measuring adaptive immunity (2022-01-04),

12. 11180813 - Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization (2021-11-23),

13. 11066705 - Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing (2021-07-20),

14. 11047008 - Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing (2021-06-29),

15. 11041202 - Method of identifying human compatible T cell receptors specific for an antigenic target (2021-06-22),

Title: Unveiling the Innovations of Harlan Saul Robins in Nucleic Acid Sequencing

Introduction: Harlan Saul Robins, a brilliant inventor based in Seattle, WA (US), has made significant contributions to the field of nucleic acid sequencing with a total of 24 patents under his name. His groundbreaking work has revolutionized the way genetic information is decoded and analyzed.

Latest Patents: Among his latest patents is the creation of synthetic strands for nucleic acid sequencing. These strands consist of rotatable solid supports with specific moieties that bind to adenine, cytosine, guanine, and thymine/uracil. The design includes position markers for rotational positioning, enabling efficient hybridization with nucleic acids. These innovations have paved the way for advanced sequencing methods and systems.

Career Highlights: Harlan Saul Robins has lent his expertise to esteemed companies such as Adaptive Biotechnologies Corporation and the Fred Hutchinson Cancer Research Center. His forward-thinking approach and dedication to advancements in genetic research have positioned him as a key figure in the industry.

Collaborations: Throughout his career, Harlan has collaborated closely with notable individuals in the field, including coworkers Ryan O. Emerson and Anna M. Sherwood. Together, they have worked on projects aimed at enhancing the accuracy and efficiency of nucleic acid profiling and sequencing.

Conclusion: Harlan Saul Robins continues to be a driving force in the field of nucleic acid sequencing, with his innovative patents and collaborative efforts shaping the future of genetic research. His ingenuity and commitment to pushing boundaries have solidified his reputation as a trailblazer in the realm of scientific innovation.

This text is generated by artificial intelligence and may not be accurate.